Gratz S, Göbel D, Behr T M, Herrmann A, Becker W
Department of Nuclear Medicine and Orthopedics, Georg August University, Göttingen, Germany.
J Rheumatol. 1999 Jun;26(6):1242-9.
To correlate the therapeutic efficacy of radiosynoviorthesis (RSO) to radiation doses achieved.
In 20 patients with known rheumatoid arthritis, radiosynoviorthesis was performed in 36 joints. Arthritis disease activity was assessed by "blood pool scintigraphy" (n = 29) score after injection of 370 MBq 99mTc-MDP, before and at 1, 2, and 5 months after the RSO in 12 patients. For semiquantitative measurements, a region-of-interest technique was applied. Synovial thickness and response to the RSO were evaluated by joint ultrasonography. Pain levels were evaluated semiquantitatively. Dosimetry (n = 20) was calculated using planar quantification according to the MIRD scheme.
The mean radiation absorbed dose of 186Re-sulfate to the whole body was 5.3+/-2.7 cGy, liver 10.0+/-8.1 cGy, spleen 20.3+/-22.9 cGy, kidneys 9.4+/-11.4 cGy, and at the injected joints of the shoulder 120.5+/-32.2 Gy, hand 130.0+/-12.6 Gy, elbow 83.6+/-38.7 Gy, and talar/subtalar joint 84.1+/-30.7 Gy. In 7 cases, where mandatory immobilization of the joint was not possible, the dose to the lymph nodes (n = 25) was 25.9+/-53.8 Gy (maximum 189 Gy) and to single lymph nodes 14.6+/-11.2 Gy (maximum 63 Gy). The reduced doses to the synovia (at 40% leakage) were: 169Er-citrate 73.10+/-25.25 Gy; 90Y-citrate 59.25+/-46.45 Gy; 186Re-sulfate 65.40+/-32.55 Gy. In cases of complete immobilization, the dose to the lymph nodes was negligible: 169Er-citrate (n = 7), whole body dose 0.4 cGy, lymph nodes 2.3 Gy, finger joints 132.3+/-34.3 Gy; 90Y-citrate (n = 6), whole body dose 15.5 cGy, liver dose 26.5 cGy, splenic dose 11.9 cGy, kidney dose 67 cGy, joint knee joint dose 130.1 Gy. Regarding therapeutic effect, mean reduction of the 99mTc-MDP blood pool activity was 41% at first month, 48% at second month, 48% at the fifth month, 48% in larger joints, and 63% in finger joints. Three and 6 months after RSO, sonography showed a mean reduction in synovial swelling: in the knee joint 1.67 and 4.38 mm, respectively; in the larger joints (shoulder, elbow, hand, talar/subtalar) 0.88/1.93 mm; and in finger joints 0.53/1.76 mm. Clinically, best results were observed in the finger joints.
将放射性滑膜切除术(RSO)的治疗效果与所达到的辐射剂量相关联。
在20例已知类风湿性关节炎患者中,对36个关节进行了放射性滑膜切除术。在12例患者中,在注射370MBq 99mTc-MDP后,通过“血池闪烁显像”(n = 29)评分在RSO前以及术后1、2和5个月评估关节炎疾病活动度。对于半定量测量,应用了感兴趣区技术。通过关节超声评估滑膜厚度和对RSO的反应。对疼痛程度进行半定量评估。根据MIRD方案使用平面定量法计算剂量测定(n = 20)。
186Re-硫酸盐对全身的平均辐射吸收剂量为5.3±2.7cGy,肝脏为10.0±8.1cGy,脾脏为20.3±22.9cGy,肾脏为9.4±11.4cGy,在注射关节处,肩部为120.5±32.2Gy,手部为130.0±12.6Gy,肘部为83.6±38.7Gy,距骨/距下关节为84.1±30.7Gy。在7例无法强制固定关节的病例中,淋巴结(n = 25)的剂量为25.9±53.8Gy(最大189Gy),单个淋巴结的剂量为14.6±11.2Gy(最大63Gy)。滑膜(在40%渗漏时)的减少剂量为:169Er-柠檬酸盐73.10±25.25Gy;90Y-柠檬酸盐59.25±46.45Gy;186Re-硫酸盐65.40±32.55Gy。在完全固定的情况下,淋巴结的剂量可忽略不计:169Er-柠檬酸盐(n = 7),全身剂量0.4cGy,淋巴结2.3Gy,手指关节132.3±3r.3Gy;YY-柠檬酸盐(n = 6),全身剂量15.5cGy,肝脏剂量26.5cGy,脾脏剂量11.9cGy,肾脏剂量67cGy,膝关节剂量130.1Gy。关于治疗效果,99mTc-MDP血池活性在第一个月平均降低41%,第二个月降低48%,第五个月降低48%,在大关节中降低48%,在手指关节中降低63%。RSO后3个月和6个月,超声检查显示滑膜肿胀平均减少:膝关节分别为1.67和4.38mm;在大关节(肩部、肘部、手部、距骨/距下关节)为0.88/1.93mm;在手指关节为0.53/1.76mm。临床上,手指关节观察到最佳效果。
1.我们观察到在没有关节固定的情况下,淋巴结的辐射吸收剂量显著更高,而滑膜的剂量更低。关节固定至关重要。2.治疗后2个月,观察到血池活性和滑膜肿胀显著降低,在接下来的几个月中进一步改善,尤其是在手指关节。3.血池活性降低、滑膜肿胀和疼痛改善之间存在很强的相关性。